Catalyst Wire Dossier Catalyst Wire Dossier

LY231514 (MTA)

LY231514 · Eli Lilly and Company
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for LY231514 (MTA), covering 2006-07-19 to 2006-07-19. Get the full timeline:

Most recent: Clinical Trial Update: A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer. [Phase 2]

See pricing